Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 4380845, 5 pages
http://dx.doi.org/10.1155/2016/4380845
Research Article

Prospective Study to Assess Progression of Renal Markers after Interruption of Tenofovir due to Nephrotoxicity

1Lluita Contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Internal Medicine Service, Autonomous University of Barcelona, Barcelona, Spain
2Statistics and Operations Research, Technical University of Catalunya, Barcelona, Spain
3IrsiCaixa Foundation, Barcelona, Spain
4Universitat de Vic-Universitat Central de Catalunya (UVIC-UCC), Barcelona, Spain

Received 22 September 2016; Revised 8 November 2016; Accepted 23 November 2016

Academic Editor: Lucia Lopalco

Copyright © 2016 Anna Bonjoch et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. E. Gallant and R. D. Moore, “Renal function with use of a tenofovir-containing initial antiretroviral regimen,” AIDS, vol. 23, no. 15, pp. 1971–1975, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. E. P. O'Donnell, K. K. Scarsi, K. M. Darin, L. Gerzenshtein, M. J. Postelnick, and F. J. Palella Jr., “Low incidence of renal impairment observed in tenofovir-treated patients,” Journal of Antimicrobial Chemotherapy, vol. 66, no. 5, pp. 1120–1126, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Scherzer, M. Estrella, Y. Li et al., “Association of tenofovir exposure with kidney disease risk in HIV infection,” AIDS, vol. 26, no. 7, pp. 867–875, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Bonjoch, P. Echeverría, N. Perez-Alvarez et al., “High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy,” Antiviral Research, vol. 96, no. 1, pp. 65–69, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. A. S. Levey, L. A. Stevens, C. H. Schmid et al., “A new equation to estimate glomerular filtration rate,” Annals of Internal Medicine, vol. 150, no. 9, pp. 604–612, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. J. L. Casado, S. Banon, C. Santiuste et al., “Prevalence and significance of proximal renal tubular abnormalities in HIV-infected patients receiving tenofovir,” AIDS, vol. 30, no. 2, pp. 231–239, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Labarga, P. Barreiro, L. Martin-Carbonero et al., “Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir,” AIDS, vol. 23, no. 6, pp. 689–696, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. A. S. Ray, T. Cihlar, K. L. Robinson et al., “Mechanism of active renal tubular efflux of tenofovir,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 10, pp. 3297–3304, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Lebrecht, A. C. Venhoff, J. Kirschner, T. Wiech, N. Venhoff, and U. A. Walker, “Mitochondrial tubulopathy in tenofovir disoproxil fumarate-treated rats,” Journal of Acquired Immune Deficiency Syndromes, vol. 51, no. 3, pp. 258–263, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. M. D. Gitman, D. Hirschwerk, C. H. Baskin, and P. C. Singhal, “Tenofovir-induced kidney injury,” Expert Opinion on Drug Safety, vol. 6, no. 2, pp. 155–164, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. M. A. Perazella, “Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy,” Kidney International, vol. 78, no. 11, pp. 1060–1063, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Cihlar, A. S. Ray, G. Laflamme et al., “Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors,” Antiviral Therapy, vol. 12, no. 2, pp. 267–272, 2007. View at Google Scholar · View at Scopus
  13. M. Ezinga, J. F. M. Wetzels, M. E. W. Bosch, A. J. A. M. Van Der Ven, and D. M. Burger, “Long-term treatment with tenofovir: prevalence of kidney tubular dysfunction and its association with tenofovir plasma concentration,” Antiviral Therapy, vol. 19, no. 8, pp. 765–771, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. W. Manosuthi, C. Sukasem, S. Thongyen, S. Nilkamhang, and S. Sungkanuparph, “ABCC21C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen,” Journal of Antimicrobial Chemotherapy, vol. 69, no. 8, pp. 2195–2201, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. B. P. Kearney, A. Mathias, A. Mittan, J. Sayre, R. Ebrahimi, and A. K. Cheng, “Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir,” Journal of Acquired Immune Deficiency Syndromes, vol. 43, no. 3, pp. 278–283, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. S. K. Gupta, “Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system,” AIDS Patient Care and STDs, vol. 22, no. 2, pp. 99–103, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. La Sociedad Española de Nefrología SEN, J. L. Gorriz, F. Gutiérrez et al., “Resumen ejecutivo del documento de consenso sobre el manejo de la patología renal en pacientes con infección por el virus de la inmunodeficiencia humana,” Enfermedades Infecciosas y Microbiología Clínica, vol. 32, no. 9, pp. 583–597, 2014. View at Publisher · View at Google Scholar
  18. P. E. Sax, D. Wohl, M. T. Yin et al., “Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials,” The Lancet, vol. 385, no. 9987, pp. 2606–2615, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Mills, G. Crofoot, C. McDonald et al., “Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: a randomized phase 2 study,” Journal of acquired immune deficiency syndromes, vol. 69, no. 4, pp. 439–445, 2015. View at Publisher · View at Google Scholar · View at Scopus